We’re grateful to receive a $4,094,561 grant to advance our #novel #SpyVector #platform that improves efficacy and boosting capability of #adenovirus-based #vaccines against current and future #pandemic viruses. Read more here: bit.ly/42txX0y

Check out @PharmaTechFocus' story about our lead #vaccine candidate for #HCMV that will begin #clinicaltrials this year. Our SpyTag/SpyCatcher protein superglue enables us to develop next generation #vaccines, just like this one. Read more here: bit.ly/423H73C

Our new Board Chair, Eddie Gray, talked with @byAmyBrown at @EvaluateVantage about the efficacy of SpyBio’s VLP #vaccine #technology and our lead #vaccine candidate for #prevention of HCMV. Read the article here: bit.ly/419ijGG

SpyBio is proud to welcome Eddie Gray as Chair of our Board. We’re grateful for his #expertise as we advance our lead vaccine candidate for HCMV toward #clinicaltrials and continue development of our cost-effective and highly scalable #technology. More at: bit.ly/40OWjAT

We’re looking forward to sharing information about how we are making the next generation #vaccines using SpyBiotech's unique protein superglue with fellow healthcare innovators at #JefferiesHealthcare in #London this week

We are pleased to announce that our CEO Mark Leuchtenberger will participate in @longwoodleaders Healthcare Leaders Webconference, speaking on 'Scientific Innovation: Launching Companies from Academia' on Sept. 21. Learn more about the conference here: bit.ly/3dt93JC

“Oxford, UK-based SpyBiotech has recruited Mark Leuchtenberger as CEO, replacing co-founder Sumi Biswas in the role, who remains president and becomes chief scientific officer."

Sumi Biswas, our co-founder, has welcomed the appointment of Mark Leuchtenberger as our new Chief Executive Officer. Sumi, who co-founded the company in 2017 as an Oxford University spin-out and has been its CEO since, becomes Chief Scientific Officer #vaccine #vaccinedevelopment

We are pleased to announce the appointment of Mark Leuchtenberger as our new Chief Executive Officer. Mark brings over 20 years of experience in the biopharmaceutical industry #vaccine #vaccinedevelopment #biotechnology

A Covid-19 vaccine being developed with SpyBiotech’s technology elicited a strong immune response in a pre-clinical study published in Science Advances. #vaccines #biotechnology #covid19research #science #Vaccine #Vaccinology #ScienceAdvances #technology

We are pleased to announce the #appointment of Simon Jones as our new VP Finance and Operations as well as the expansion of the scientific team with four new hires. Simon brings a wealth of experience having held senior finance roles in a number of biotech companies #CFO #newhire

Congratulations to our co-founder & CEO Sumi Biswas on being featured in the @FT as one of the top 30 UK female #entrepreneurs to watch, highlighting some of the most impactful disrupters and innovators in their field @JennerInstitute @UniofOxford #innovation #healthtech #biotech

Our technology could offer effective solutions for COVID-19 variants & potentially across a range of diseases for which there are no approved treatments  Read more in the @theGuardian supplement today with @gavi, @sanofi, @EuropeVaccine, @asda, @IFPMA, @Intravacc, @MediaplanetUK

Our #pioneeringtechnology, the proprietary protein superglue SpyTag/SpyCatcher, enables us to develop safe and highly effective #vaccines with greater ease and speed. #ValueofVaccinesCampaign2021 Click to find out more

Congratulations to our Co-founder and Chief Executive Officer, Sumi Biswas for being recognised in @Beauhurst’s list of ‘Top 50 Female Entrepreneurs to watch’, aimed at highlighting the best and brightest emerging talents! beauhurst.com/blog/female-en…

Proud to continue our work with the @SerumInstIndia to develop a COVID-19 vaccine based on VLP technology. #COVID19Vaccine #COVID19India

Join our Founder & CEO Sumi Biswas in her discussion of SpyBiotech's proprietary technology and potential at OIC's second 'Celebration of British Innovation and New Technologies' webinar. To listen in, sign-up here. oxfordinvestmentconsultants.…

We are pleased to be included in this article by @TheNationalNews about the next wave of Covid-19 vaccines. Our "superglue" technology from @JennerInstitute @UniofOxford is currently in clinical trials being conducted by @SerumInstIndia #vaccines #CovidVaccine #biotech

On this #IWD2021, we proudly celebrate women in the life sciences industry, including our founder & CEO Sumi Biswas, whose drive inspired our proprietary ‘protein superglue’, to aid in the global fight against COVID-19 oxfordsciencesinnovation.com…

The appointments of Dan Menichella as non-executive director and Norman Begg as scientific advisor will support us as we build out our vaccine technology platform and advance into clinical development #vaccine #covid19 #infectiousdiseases spybiotech.com/news/spybiote…